Protective effects of plicatin B on micronucleus induction in cultured human lymphocytes by different mutagens

Food and Chemical Toxicology

Volumn 47, Issue 1, 2009, Pages 124-128

  Eventi, Annalisa ^a   Lubrano, Valter ^b   Scarpato, Roberto ^c   Turchi, Gino ^a  

^a CNR   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Chalcone plicatin B; Cytotoxicity; Micronucleus

Indexed keywords

BLEOMYCIN; CHALCONE; HYDROGEN PEROXIDE; MITOMYCIN C; MUTAGENIC AGENT; PLICATIN B; UNCLASSIFIED DRUG;

ARTICLE; CLASTOGENICITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MICRONUCLEUS; MUTAGENICITY;

ACRYLATES; ADULT; BLEOMYCIN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN PEROXIDE; LYMPHOCYTES; MALE; MICRONUCLEUS TESTS; MITOMYCIN; MOLECULAR STRUCTURE; MUTAGENS;

EID: 58149197616     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2008.10.017     Document Type: Article

References (55)

1. Anto R.J., Sukumaran K., Kuttan G., Rao M.N.A., Subbaraju V., and Kuttan R. Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Lett. 97 (1995) 33-37
2. Akihisa T., Tokuda H., Ukiya M., Iizuka M., Schneider S., Ogasawara K., Mukainaka T., Iwatsuki K., Suzuki T., and Nishino H. Chalcones, coumarins, and flavanones from the exudate of Angelica keiskei and their chemopreventive effects. Cancer Lett. 201 (2003) 133-137
3. Baldi, S., Maurich, T., Lubrano, V., Turchi, G., 2003. Antioxidant properties of the chalcone plicatin B. In: Proceedings of Eighth International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis, Pisa, Italy, 4-8 October, p. 14.
4. Belisario M.A., Pecce R., Garofano A., Cannolo N., and Malori A. Erythrocyte enzymes catalyze 1-nitropyrene and 3-nitrofluoranthene nitroreduction. Toxicology 108 (1996) 101-108
5. Bhat B.A., Dhar K.L., Puri S.C., Saxema A.K., Shanmugavel M., and Qazi G.N. Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents. Biorg. Med. Chem. Lett. 15 (2005) 3177-3180
6. Bors W., Michel C., and Saran M. Flavonoids as antioxidants: determination of radical scavenging efficiencies. Methods Enzymol. 186 (1990) 343-355
7. ++ ions: implications for their antioxidant properties. Biochem. J. 330 (1998) 1173-1178
8. Burger R.M., Peisach J., Blumberg W.E., and Horwitz S.B. Iron-bleomycin interactions with oxygen and oxygen analogues: effects on spectra and drug activity. J. Biol. Chem. 254 (1979) 10906-10911
9. Byrnes R.W., and Petering D.H. DNA strand breakage in isolated nuclei injected to bleomycin or hydrogen peroxide. Biochem. Pharmacol. 48 (1994) 575-582
10. Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc. Res. 68 (2005) 26-36
11. Calliste C.-A., Le Bail J.-C., Trouillas P., Pouget C., Habrioux G., Chulia A.-J., and Doroux J.-L. Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities. Anticancer Res. 21 (2001) 3949-3956
12. Cummings J., Spanswick V.J., and Smyth J.F. Re-evaluation of the molecular pharmacology of mitomycin C. Eur. J. Cancer 31A (1995) 1928-1933
13. Cummings J. The role of reductive enzymes in cancer cell resistance to mitomycin C. Drug Resistance Updates 3 (2000) 143-148
14. De Flora S., and Ramel C. Mechanisms of inhibitors of mutagenesis and carcinogenesis classification and overview. Mutat. Res. 202 (1988) 285-306
15. De Vincenzo R., Ferlini C., Distefano M., Saggini C., Riva A., Bombardelli E., and Morazzoni P. In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chem. Pharm. 46 (2000) 305-312
16. Ducki S., Forrest R., Hadfield J.A., kendall A., Nicholas J.L., McGown A.T., and Rennison D. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. 8 (1998) 1051-1056
17. Edenhanrder R., and Tang X. Inhibition of the mutagenicity of 2-nitrofluorene, 3-nitrofluoranthene and 1-nitropyrene by flavonoids, coumarins, quinines and other phenolic compounds. Food Chem. Toxicol. 35 (1997) 357-372
18. Esterbauer H., and Ramos P. Chemistry and pathophysiology of oxidation of LDL. Rev. Physiol. Biochem. Pharmacol. 127 (1995) 31-64
19. Fenech M. Optimisation of micronucleus assays for biological dosimetry. In: Gledhill B.L., and Mauro F. (Eds). New Horizons in Biological Dosimetry (1991), Wiley-Liss 373-386
20. Haenen G.R.M.M., Arts M.J.T.J., Bast A., and Coleman M.D. Structure and activity in assessing antioxidant activity in vitro and in vivo. A critical appraisal illustrated with the flavonoids. Environ. Toxicol. Pharmacol. 21 (2006) 191-198
21. Havsteen B.H. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 96 (2002) 67-202
22. Herencia F., Ferràndiz M.L., Ubeda A., Dominguez J.N., Charris J.E., Lobo G.M., and Alcarez M.j. Synthesis and anti-inflammatory activity of chalcone derivatives. Bioorg. Med. Chem. Lett. 8 (1998) 1169-1174
23. Iwashita J., Kodama S., Nakashima M., Sasaki H., Taniyama K., and Waranabe M. Induction of micronuclei in CHO cells by bleomycin but not by x-irradiation in decresed by treatment with HMG-CoA reductase inhibitors. J. Radiat. Res. 46 (2005) 191-195
24. 32Pi-incorporation into phospholipids of HeLa cells promoted by 12-O-tetradecanoyl-phorbol 13 acetate (TPA). Biol. Pharm. Bull. 18 (1995) 1710-1713
25. Johnson I.T. New approaches to the role of diet in the prevention of cancer of the alimentary tract. Mutat. Res. 551 (2004) 9-28
26. Kada T., Inoue T., Ohta T., and Shirasu Y. Antimutagens and their mode of action. In: Shankel D.M., Hartman P.E., Kada T., and Hollanender A. (Eds). Antimutagenesis and Anticarcinogenesis Mechanisms (1986), Plenum, New York 181-198
27. Kim D.Y., Kim K.-H., Kim N.D., Lee K.Y., Han C.K., Yoon J.H., Moon S.K., Lee S.S., and Baik L.S. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using pharmacophore binding model with tubulin. J. Med. Chem. 49 (2006) 5664-5670
28. Kirsch-Volders M., Sofuni T., Aardema M., Albertini S., Eastmond D., Fenech M., Ishidate Jr. M., Lorge E., Norppa H., Surrallés J., Von der Hude W., and Wakata A. Report from the in vitro micronucleus assay working group. Environ. Mol. Mutat. 35 (2000) 167-172
29. Lapeyre C., Delomenède M., Bedos-Belval F., Duran H., Nègre-Salvayre A., and Baltas M. Design, synthesis, and evaluation of pharmacological properties of cinnamic derivatives as antiatherogenic agents. J. Med. Chem. 48 (2005) 8124-8155
30. Lazo J.S., Sebti S.M., and Schellens J.H. Bleomycin. Cancer Chemoter. Biol. Response Modif. 16 (1996) 39-47
31. Lawrence N.J., McGown A.T., Ducki S., and Hadfield J.A. The interaction of chalcones with tubulin. Anti-Cancer Drug Des. 15 (2000) 135-141
32. LeBail J.C., Varnat F., Nicolas J.C., and Habrioux G. Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by flavonoids. Cancer Lett. 130 (1998) 209-216
33. 2. Drug Chem. Toxicol. 30 (2007) 311-325
34. Mir L.M., Tounekti O., and Orlowski S. Bleomycin: revival of an old drug. Gen. Pharmacol. 27 (1996) 745-748
35. Menon S.R., Patel V.K., Mitscher L.A., Shih P., Pillai S.P., and Shankel D.M. Structure-antimutagenic activity relationship study of plicatin B. J. Nat. Prod. 62 (1999) 102-106
36. Miranda C.L., Aponso G.L.M., Stevens J.F., Deinzer M.L., and Bulher D.R. Prenylated chalcones and flavanones as inducers of quinine reductase in mouse Hepa 1c1c7 cells. Cancer Lett. 149 (2000) 21-29
37. Miranda C.L., Stevens J.F., Ivanov V., McCall M., Frei B., Deinzer M.L., and Bulher D.R. Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. J. Agric. Food Chem. 48 (2000) 3876-3884
38. Mitscher L.A., Telikepalli H., McGhee E., and Shankel D.M. Natural antimutagenic agents. Mutat. Res. 350 (1996) 143-152
39. Nerya O., Musa R., Khatib S., Tamir S., and Vaya J. Chalcones as potent tyrosinase inhibitors: the effect of hydroxyl positions and numbers. Phytochemistry 65 (2004) 1389-1395
40. Norppa H. Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes. Environ. Health Perspect. 105 Suppl. 4 (1997) 829-835
41. Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones. Eur. J. Med. Chem. 42 (2007) 125-137
42. Oliveira R.J., Ribeiro L.R., Fernanda da Silva A., Matuo R., and Mantovani M.S. Evaluation of antimutagenic activity and mechanisms of action of β-glucan from barley, in CHO-k1 and HTC cell lines using the micronucleus test. Toxicol. In Vitro 20 (2006) 1225-1233
43. Pietta P.-G. Flavonoids as antioxidants. J. Nat. Prod. 63 (2000) 1035-1042
44. Poersch A., Vieira dos Santos F., Medeiros Maciel M.A., Pereira da Camara J.K., Neuma de Castro Dantas T., and Mara de Syllos Còlus I. Protective effect of DCTN (transdehydrocrotonin) against induction of micronuclei and apoptosis by different mutagenic agents. Mutat. Res. 629 (2007) 14-23
45. Povirk L.F. DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin an other enediynes. Mutat. Res. 355 (1996) 71-89
46. Rodriguez R.J., Miranda C.L., Stevens J.F., Deinzer M.L., and Bulher D.R. Influence of prenylated and non-prenylated flavonoids on liver microsomial lipid peroxidation and oxidative injury in rat hepatocytes. Food Chem. Toxicol. 39 (2001) 437-445
47. Sartorelli A.C., Hodnik W.F., and Belcourt M.F. Mitomycin C, a prototype bioreductive agent. Oncol. Res. 6 (1994) 501-508
48. Sasaki Y.F., Matsumoto K., Imanishi H., Watanabe M., Ohta T., Shirasu Y., and Tutikawa K. In vivo anticlastogenic and antimutagenic affects of tannic acid in mice. Mutat. Res. 244 (1990) 43-47
49. Stubbe J., and Kozarich J.W. Mechanisms of bleomycin-induced DNA degradation. Chem. Rev. 87 (1987) 1107-1136
50. Surrallés J., Xamena N., Creus A., Catalán J., Norppa H., and Marcos R. Induction of micronuclei by five pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures. Mutat. Res. 341 (1995) 169-184
51. Surh Y.-J., and Fergusson L.R. Dietary and medicinal antimutagens and anticarcinogens: molecular mechanisms and chemiopreventive potential-highlights of a symposium. Mutat. Res. (2003) 1-8
52. Takatomo S., Midori H., Kiyotaka Y., Masaki K., and Toshio S. Application of mFISH for the analysis of chemically-induced chromosomal aberrations: a model for the formation of triradial chromosomes. Mutat. Res. 504 (2002) 57-65
53. Torigoe T., Arisawa M., Itoh S., Fujiu M., and Maruyama H.B. Anti-mutagenic chalcones: antagonizing the mutagenicity of benzo(a)pyrene on Salmonella typhimurium. Biochem. Biophys. Res. Commun. 112 (1983) 833-842
54. van Acker S.A.B., van Balen G.P., van der Berg D.-J., Bast A., and van der Vjigh W.J.F. Influence of iron chelation on the antioxidant activity of flavonoids. Biochem. Pharmacol. 56 (1998) 935-943
55. 2 and γ-irradiation with the alkaline comet assay. Mutat. Res. 383 (1997) 71-80